Detailing a Defense Department program to develop implantable biomedical technology

Alfred Mann BION technology uses FCC regulated wireless spectrum, usingvAdvanced Bionics, Round Trip LLC, Mannkind Corp and Second Sight LLC and other intellectual property mostly from William Heetderks at the National Institutes of Health (NIH) NIBIB. Alfred Mann receives funding and contracts from DARPA, Dept. of Defense, Dept. of Energy, NIST/ATP and works collectively with Argonne National Laboratory, JPL/NASA, Pritzker Institute, Illinois Institute of Technology, Lawrence Karr, Kent Kresa and others.

In addition to interacting in real-time using the experimental FCC license awarded to the Mann Foundation, the unlawful use of devices may occur automatically in a “closed-loop” mode as per Loeb’s patent #6,658,301 and other patents filed by Mann Foundation principals governing the automated “closed-loop” mode.

Closed-Loop Operation, Default Configuration In addition to interacting and controlling implanted device operation via wireless connection, a system has been developed that allows the devices to continue functioning, even without an RF power or data signal. Each device has a microscopic amount of thin-film memory that stores "default stimulation parameters". The devices can be powered from any AM modulated RF signal, however these devices also feature hybrid tantalum/capacitor electrodes. The tantalum acts as both a capacitor, and an electrode that interfaces with tissue, and the tantalum capacitor is able to charge by itself using the electrolytes present in the body tissue. In short, the devices may continue to operate in an automated, closed-loop fashion, even if the subject is in a RF free environment. Many patents filed by the Alfred Mann Foundation address the closed-loop mode as well as the ability to control implanted devices using numerous wireless communication modes which include modulated ultrasonic signal, magnetic inductive link, and RF frequencies. (a)

Preventing devices from being detected or localized by clinical radiology methods In order to prevent implanted devices from being found and removed by medical personnel, it was important that the devices avoid generating a contrast artifiact during radiology methods such as Magnetic Resonance (MRi_, Computerized Tomography (CT), Ultrasound, or traditional x-ray radiography. In order to accomplish this, the devices would have to be very small, but more importantly, they would have to be constructed using completely non-ferous materials. While in Toronto, Gerald Loeb of the Mann Foundation worked with radiologist John Rossiter under an NIH contract. The double-blind protocol was ideally suited to allow Loeb to test different variations and determine what radiologists could see, and could not see, during radiology efforts. The bulk of the devices consist of integrated tantalum capacitor/electrodes and it was determined that the tantalum contained trace amounts of ferrous contaminants and metals. These trace amounts were a problem for the Mann Foundation because it was just enough to cause a contrast artifact on radiology film. The trace amounts of other metals were exteremely minimal and were of no concern to traditional suppliers of tantalum (such as AVX) because the medical industry had no need to hide tantalum from radiologists. The Mann Foundation began trying to source new, extremely pure tantalum, and also struggled to explain why. In a quarterly progress report submitted to Bill Heetderks as part of their NIH funding, Schulman wrote that "A lawyer for the tantalum company called us and stated that they could not supply tantalum for implanted devices because the word 'silicon sounds too much like silicone' and feared litigation". There are tantalum suppliers that have been supplying manufacturers of pacemakers and cochlear implants for many years, and there is not a problem finding tantalum for use in implanted devices. Schulman knew this of course because he is a principal at Advanced Bionics (Clarion cochlear implant) and Pacesetter/Siemens (pacemakers). Regardless, it was a fabricated excuse concocted to explain why they would spend the next four months sourcing a new supply of tantalum. In the end, Wilson Greatbatch Technologies was created in 1997 to supply the government and Mann Foundation with tantalum that could be hidden from clinical radiologists. Schulman's excuse about not being able to find a tantalum supplier for four months because the suppliers feared litigation if their tantalum was used in medical devices was pathetic. When Gerald Loeb submitted his grant application to Bill Heetderks at the NIH/NICHD, he also was forced to explain why they needed such "special" tantalum, however Loeb concoted his own excuse. Loeb wrote "the trace amounts of contaminants caused the tantalum not to be able to withstand the high pre-charge voltage required for device operation" and thus, required yet again, "special tantalum".

Testosterone for behavior modification Gerald Loeb of the Mann Foundation investigated adding testosterone into the epoxy coating of devices which could then be released in a controlled manner into research subjects. This is discussed in his patent 6,175,764 and is also discussed in a research paper Loeb and his wife, F.J. Richmond attached to another quarterly progress report submitted to Heetderks under Mann's NIH contracts. The paper goes on to state that they elevated circulating levels of testosterone in cats by as much as 5000%, or 50x above normal, and noted increased rage and promiscuity. The difficult thing for Loeb and Schulman is explaining how 50x elevated testosterone combined with electrical stimulation was supposed to be therapeutic. There were previous studies that showed testosterone did not treat muscular disuse atrophy, so they claimed to be investigating treating disuse atrophy again, only this time, Schulman and Loeb claimed to have "special testosterone" provided by "Dr. Schaffie of Innovative Research Products of America". In the end, Schulman and Loeb's paper claimed that the manufactures claims were erroneous and (suprise) the testosterone was innefective in treating disuse atrophy. They did however, learn how to instigate violent acts of aggression and rage using testosterone to "supplement and enhance the effects of electrical stimulation". It is no wonder that Loeb is now under subcontract with the Naval Space Warfare Center (SPAWAR prime contract N6600106C8005). Is there any doubt that this technology is not therapeutic and has been used for evil against American citizens?

More Device Images | click here